Edition:
United Kingdom

Lupin Ltd (LUPN.NS)

LUPN.NS on National Stock Exchange of India

882.55INR
11:29am BST
Change (% chg)

Rs21.80 (+2.53%)
Prev Close
Rs860.75
Open
Rs860.70
Day's High
Rs887.75
Day's Low
Rs857.50
Volume
2,487,594
Avg. Vol
3,331,849
52-wk High
Rs1,090.00
52-wk Low
Rs723.65

Chart for

About

Lupin Limited is a pharmaceutical company. The Company is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across the world. The Company offers products in the cardiovascular, diabetology, asthma, pediatrics, central... (more)

Overall

Beta: -0.05
Market Cap(Mil.): Rs469,414.59
Shares Outstanding(Mil.): 451.84
Dividend: 7.50
Yield (%): 0.72

Financials

  LUPN.NS Industry Sector
P/E (TTM): 23.14 30.93 32.76
EPS (TTM): 44.89 -- --
ROI: -- 15.07 14.61
ROE: -- 16.59 16.33

UPDATE 1-India's Lupin Q1 profit misses estimate by wide margin

Aug 8 Drugmaker Lupin Ltd posted a bigger-than-expected fall in first-quarter profit on Wednesday, hurt by declining sales in the United States and Japan.

08 Aug 2018

India's Lupin quarterly profit falls 43 pct

Aug 8 Drugmaker Lupin Ltd posted a 43 percent fall in first-quarter profit on Wednesday, widely missing analysts' estimates.

08 Aug 2018

BRIEF-Omeros Says Entered Into Settlement Agreement And Consent Judgment With Lupin Ltd and unit Lupin Pharmaceuticals - SEC Filing

* OMEROS SAYS ENTERED INTO SETTLEMENT AGREEMENT AND CONSENT JUDGMENT WITH LUPIN LTD, SUBSIDIARY LUPIN PHARMACEUTICALS - SEC FILING

24 May 2018

UPDATE 2-India's Lupin expects U.S. drug pricing pressure to ease in 2019

* U.S. sales fall 21.1 pct; India sales up 14 pct (Adds management comments from conference call)

15 May 2018

India's Lupin posts surprise Q4 loss on one-time charge

May 15 Lupin Ltd, India's second-largest drugmaker by revenue, reported a surprise loss in its fiscal fourth quarter on Tuesday, due to a one-time charge.

15 May 2018

BRIEF-India's Lupin Gets FDA Approval For Generic Temovate Ointment, 0.05 Percent

* GETS FDA APPROVAL FOR GENERIC TEMOVATE OINTMENT, 0.05 PERCENT

07 May 2018

BRIEF-India's Lupin Gets FDA Nod For Generic Xenazine Tablets, 12.5 Mg And 25 Mg

* SAYS CO RECEIVES FDA APPROVAL FOR GENERIC XENAZINE TABLETS, 12.5 MG AND 25 MG Source text - http://bit.ly/2qUd2T4 Further company coverage:

23 Apr 2018

BRIEF-India's Lupin Gets Tentative U.S. FDA Nod For Generic Androgel, 1.62 Pct

* SAYS CO RECEIVES TENTATIVE FDA APPROVAL FOR GENERIC ANDROGEL, 1.62 PERCENT Source text - https://bit.ly/2HEhHk8 Further company coverage:

17 Apr 2018

BRIEF-Lupin's Pithampur Unit 1 Facility Gets EIR From U.S. FDA

* SAYS PITHAMPUR UNIT 1 FACILITY RECEIVES ESTABLISHMENT INVESTIGATION REPORT (EIR) FROM US FDA

06 Apr 2018

BRIEF-Lupin's Goa Facility Completes Successful U.K MHRA Inspection

* SAYS CO'S GOA FACILITY COMPLETES SUCCESSFUL UK MHRA INSPECTION

03 Apr 2018

Earnings vs. Estimates